BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Rhea-AI Summary

BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company focused on oncology and rare diseases, has announced it will release its Q3 2024 financial results on November 25, 2024, before U.S. markets open. The company will host a conference call at 8:30 a.m. EST, featuring CEO Philip Serlin. The call will be accessible via phone and webcast through the company's website, with replay available until November 27, 2024.

Management to Hold Conference Call at 8:30 a.m. EST

TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until November 27, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  

CONTACTS:

United States
John Lacey 
BioLineRx 
IR@biolinerx.com

Israel
Moran Meir 
LifeSci Advisors, LLC 
moran@lifesciadvisors.com

Logo - https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2024-results-on-november-25-2024-302311395.html

SOURCE BioLineRx Ltd.

FAQ

When will BioLineRx (BLRX) release its Q3 2024 earnings?

BioLineRx (BLRX) will release its Q3 2024 earnings on Monday, November 25, 2024, before U.S. markets open.

What time is BioLineRx's (BLRX) Q3 2024 earnings call?

BioLineRx's (BLRX) Q3 2024 earnings conference call is scheduled for 8:30 a.m. EST on November 25, 2024.

How can I access BioLineRx's (BLRX) Q3 2024 earnings call?

You can access the call by dialing +1-888-281-1167 (U.S.) or +972-3-918-0685 (international), or through the webcast available on the company's website.

Until when will BioLineRx's (BLRX) Q3 2024 earnings call replay be available?

The earnings call replay will be available until November 27, 2024, accessible by dialing +1-888-295-2634 (U.S.) or +972-3-925-5904 (international).